Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE.
Morice P, Scambia G, Abu-Rustum NR, Acien M, Arena A, Brucker S, Cheong Y, Collinet P, Fanfani F, Filippi F, Eriksson AGZ, Gouy S, Harter P, Matias-Guiu X, Pados G, Pakiz M, Querleu D, Rodolakis A, Rousset-Jablonski C, Stepanyan A, Testa AC, Macklon KT, Tsolakidis D, De Vos M, Planchamp F, Grynberg M.
Lancet Oncol. 2024 Nov;25(11):e602-e610. doi: 10.1016/S1470-2045(24)00262-6. Epub 2024 Aug 28.
PMID:39216500
Adenomatoid tumor of the uterus: analysis of misdiagnosed cases and a literature review.
Li YY, Kan GJ, Wang Q, Guo S, Wu CX, Zhu J.
J Int Med Res. 2024 Oct;52(10):3000605241282389. doi: 10.1177/03000605241282389.
PMID:39394879
Management and prognosis of endometrioid borderline tumors of the ovary.
Uzan C, Berretta R, Rolla M, Gouy S, Fauvet R, Darai E, Duvillard P, Morice P.
Surg Oncol. 2012 Sep;21(3):178-84. doi: 10.1016/j.suronc.2012.02.002. Epub 2012 Mar 13.
PMID:22418038
Use of HC2 to triage women with borderline and mild dyskaryosis in the UK.
Arbyn M, Roelens J, Martin-Hirsch P, Leeson S, Wentzensen N.